As a convenient once-daily pill, orforglipron may provide a new option and, if approved, could be readily manufactured and launched at scale for use by people around the world, said David Ricks, CEO of Lilly, in a statement
Diabetes Care 28 , 10921100 (2005)
Retatrutide is an unlicensed investigational GLP-1, GIP, and glucagon triple receptor agonist
However, without standardized testing, there is no assurance that compounded versions deliver consistent or predictable results
MBX 4291, dual GLP-1/GIP co-agonist prodrug designed for potential once-monthly dosing and improved tolerability in obesity Recent Highlights: In June 2026, MBX Biosciences announced data that demonstrated sustained benefit of its once-weekly Canvuparatide as a potential PTH replacement therapy in chronic hypoparathyroidism